BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li GF, An XX, Yu Y, Jiao LR, Canarutto D, Yu G, Wang G, Wu DN, Xiao Y. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut 2021;70:1806-8. [PMID: 33172925 DOI: 10.1136/gutjnl-2020-323366] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Shah S, Halvorson A, McBay B, Dorn C, Wilson O, Tuteja S, Chang KM, Cho K, Hauger R, Suzuki A, Hunt C, Siew E, Matheny M, Hung A, Greevy R, Roumie C. Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. Gut 2022;71:1447-50. [PMID: 34663578 DOI: 10.1136/gutjnl-2021-325701] [Reference Citation Analysis]
2 Wu DN, Jiao LR, Li GF, Yu G. Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19. Eur J Clin Pharmacol 2022. [PMID: 35575912 DOI: 10.1007/s00228-022-03319-w] [Reference Citation Analysis]
3 Shafrir A, Benson AA, Katz LH, Hershcovici T, Bitan M, Paltiel O, Calderon-margalit R, Safadi R, Shauly-aharonov M. The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study. Front Pharmacol 2022;13:791074. [DOI: 10.3389/fphar.2022.791074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shen H, Zhang N, Liu Y, Yang X, He Y, Li Q, Shen X, Zhu Y, Yang Y. The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. Front Pharmacol 2021;12:805535. [PMID: 35069217 DOI: 10.3389/fphar.2021.805535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Baré M, Lleal M, Ortonobes S, Gorgas MQ, Sevilla-Sánchez D, Carballo N, De Jaime E, Herranz S; MoPIM study group. Factors associated to potentially inappropriate prescribing in older patients according to STOPP/START criteria: MoPIM multicentre cohort study. BMC Geriatr 2022;22:44. [PMID: 35016636 DOI: 10.1186/s12877-021-02715-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zevit N, Chehade M, Leung J, Marderfeld L, Dellon ES. Eosinophilic Esophagitis Patients Are Not at Increased Risk of Severe COVID-19: A Report From a Global Registry. J Allergy Clin Immunol Pract 2022;10:143-149.e9. [PMID: 34688963 DOI: 10.1016/j.jaip.2021.10.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gonzalez I, Lindner C, Schneider I, Morales MA, Rojas A. Inflammation at the crossroads of Helicobacter pylori and COVID-19. Future Microbiol 2022;17:77-80. [PMID: 34915742 DOI: 10.2217/fmb-2021-0250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. Eur J Clin Pharmacol 2021. [PMID: 34817624 DOI: 10.1007/s00228-021-03255-1] [Reference Citation Analysis]
9 Marasco G, Cremon C, Barbaro MR, Salvi D, Cacciari G, Kagramanova A, Bordin D, Drug V, Miftode E, Fusaroli P, Mohamed SY, Ricci C, Bellini M, Rahman MM, Melcarne L, Santos J, Lobo B, Bor S, Yapali S, Akyol D, Sapmaz FP, Urun YY, Eskazan T, Celebi A, Kacmaz H, Ebik B, Binicier HC, Bugdayci MS, Yağcı MB, Pullukcu H, Kaya BY, Tureyen A, Hatemi İ, Koc ES, Sirin G, Calıskan AR, Bengi G, Alıs EE, Lukic S, Trajkovska M, Hod K, Dumitrascu D, Pietrangelo A, Corradini E, Simren M, Sjolund J, Tornkvist N, Ghoshal UC, Kolokolnikova O, Colecchia A, Serra J, Maconi G, De Giorgio R, Danese S, Portincasa P, Di Stefano M, Maggio M, Philippou E, Lee YY, Venturi A, Borghi C, Zoli M, Gionchetti P, Viale P, Stanghellini V, Barbara G; and the GI-COVID19 Study Group. Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. Am J Gastroenterol 2021. [PMID: 34751672 DOI: 10.14309/ajg.0000000000001541] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
10 Chiu L, Shen M, Lo CH, Chiu N, Chen A, Shin HJ, Prsic EH, Hur C, Chow R, Lebwohl B. Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis. PLoS One 2021;16:e0259514. [PMID: 34735523 DOI: 10.1371/journal.pone.0259514] [Reference Citation Analysis]
11 Veettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P, Lee YY, Nair AB, Antony PT, Ford AC, Chaiyakunapruk N. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol 2021. [PMID: 34622475 DOI: 10.1111/bcp.15103] [Reference Citation Analysis]
12 Lee SW, Yang JM, Yoo IK, Moon SY, Ha EK, Yeniova AÖ, Cho JY, Kim MS, Shin JI, Yon DK. Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort. Gut 2021;70:2013-5. [PMID: 33303566 DOI: 10.1136/gutjnl-2020-323672] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
13 Lu CX, An XX, Yu Y, Jiao LR, Canarutto D, Li GF, Yu G. Pooled Analysis of Gastric Emptying in Patients With Obesity: Implications for Oral Absorption Projection. Clin Ther 2021;43:1768-88. [PMID: 34482960 DOI: 10.1016/j.clinthera.2021.08.006] [Reference Citation Analysis]
14 Megyeri K, Dernovics Á, Al-Luhaibi ZII, Rosztóczy A. COVID-19-associated diarrhea. World J Gastroenterol 2021; 27(23): 3208-3222 [PMID: 34163106 DOI: 10.3748/wjg.v27.i23.3208] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
15 Sebastián Domingo JJ. Proton pump inhibitors in the COVID-19 pandemic. Gastroenterol Hepatol 2021:S0210-5705(21)00166-7. [PMID: 34051314 DOI: 10.1016/j.gastrohep.2021.04.008] [Reference Citation Analysis]
16 Israelsen SB, Ernst MT, Lundh A, Lundbo LF, Sandholdt H, Hallas J, Benfield T. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:1845-1854.e6. [PMID: 33989790 DOI: 10.1016/j.cgh.2021.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
17 Zippi M, Fiorino S, Budriesi R, Micucci M, Corazza I, Pica R, de Biase D, Gallo CG, Hong W. Paradoxical relationship between proton pump inhibitors and COVID-19: A systematic review and meta-analysis. World J Clin Cases 2021; 9(12): 2763-2777 [PMID: 33969059 DOI: 10.12998/wjcc.v9.i12.2763] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
18 Hirota K, Lambert DG. Anaesthesia-related drugs and SARS-CoV-2 infection. Br J Anaesth 2021;127:e32-4. [PMID: 33934887 DOI: 10.1016/j.bja.2021.03.026] [Reference Citation Analysis]
19 Homolak J, Kodvanj I, Trkulja V. An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19. Clin Drug Investig 2021;41:287-9. [PMID: 33606199 DOI: 10.1007/s40261-021-01007-8] [Reference Citation Analysis]